Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $275.00

Posted by Brian Himes on Aug 31st, 2026

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its target price hoisted by Needham & Company LLC from $240.00 to $275.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 32.29% from the company’s previous close.

Several other research firms have also recently weighed in on RVMD. Truist Financial increased their price objective on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research report on Thursday. Oppenheimer upped their price target on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Royal Bank Of Canada lifted their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Wolfe Research reissued an “outperform” rating and issued a $220.00 price objective on shares of Revolution Medicines in a research note on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $200.74.

Get Our Latest Report on Revolution Medicines

Revolution Medicines Price Performance

Revolution Medicines stock opened at $207.88 on Monday. The stock’s 50 day moving average is $193.33 and its 200 day moving average is $148.95. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The firm has a market cap of $44.56 billion, a P/E ratio of -23.57 and a beta of 1.39. Revolution Medicines has a one year low of $37.56 and a one year high of $224.31.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the business earned ($1.31) EPS. As a group, research analysts expect that Revolution Medicines will post -8.85 EPS for the current year.

Insider Transactions at Revolution Medicines

In other news, Director Sushil Patel sold 5,580 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director owned 21,656 shares of the company’s stock, valued at $4,071,111.44. This represents a 20.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark A. Goldsmith sold 80,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This represents a 23.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in shares of Revolution Medicines by 26,920.9% during the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company’s stock worth $8,363,803,000 after purchasing an additional 44,494,074 shares during the period. Alphabet Inc. acquired a new stake in Revolution Medicines in the 2nd quarter valued at $551,843,000. Norges Bank bought a new stake in Revolution Medicines during the 4th quarter valued at $195,568,000. Avoro Capital Advisors LLC bought a new stake in Revolution Medicines during the 4th quarter valued at $172,840,000. Finally, Polar Capital Holdings Plc raised its holdings in Revolution Medicines by 321.2% during the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after buying an additional 1,535,686 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

(Get Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.